Sirnaomics In raises $22m led by Hong Kong’s CR-CP Life Sciences Fund

Hands of clinician holding steel tools during scientific experiment in laboratory (Photo Source: Internet Archive)

Sirnaomics In, a US-headquartered biopharmaceutical company with operations in China, has raised $22 million in a Series C2 funding round, led by Hong Kong-based CR-CP Life Sciences Fund, according to an announcement.

CR-CP Life Sciences Fund is a joint venture between Hong Kong-based China Resources Group and Thailand’s Charoen Pokphand Group.

Other investors joining the round are Shanghai-based Rich Yield Capital, Rolling Boulder Investment from Shenzhen and US-based Legend Sky Investment.

This marks the second tranche of Series C funding round for the company, that took the total corpus being raised in this round to $47 million. The first round of Series C funding was completed in June last year at $25 million, led by Yuexiu New Industrial Investment. Other investors who participated in the round were Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment.

“Completion of C round of financing strongly positions Sirnaomics for the next phase of technology and product development, in particular for our clinical studies to treat various types of cancer,” said Patrick Lu, president and chief executive officer, Sirnaomics Inc.

Sirnaomics plans to use a part of the funds to support its clinical programs for RNAi therapeutics for treatment of a range of cancer and fibrotic diseases. The clinical developments are done in the US and China, the two major markets of oncology and fibrosis. The other part of the money will be used to advance its technology platforms.

The company’s lead product is undergoing a phase II clinical study and is being investigated for treatment of non-melanoma skin cancer.

Prior to the Series C round, Sirnaomics has raised $10 million in a Series B round, led by Hong Kong-based venture capital firm Value Measured Investment Ltd.

Also Read:

China: Qiming leads $20M series A in Connect Biopharmaceuticals to advance clinical study

IFC may offer $148m loan to China’s Jointown Pharmaceutical Group

GIC-backed Chinese biopharma firm CStone raises $285m in HK IPO

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.